

## **Dr. Mark Miller**

### **PUBLICATIONS**

Exposure of passengers and flight crew to *Mycobacterium tuberculosis* on commercial aircraft, 1992-1995. Morbidity and Mortality Weekly Report. 1995. 44:137-40.

Influenza and pneumococcal vaccination levels in persons > 65 years of age: 1973-1993. Morbidity and Mortality Weekly Report. 1995:506-515.

The Cuba Neuropathy Field Investigation Team. Epidemic optic neuropathy in Cuba: Clinical characterization and risk factors. New England Journal of Medicine. 1995;333:1176-82.

**Miller M**, Sutter R, Strebel P, Hadler S. Cost-effectiveness of integrating inactivated poliomyelitis vaccine into the routine US vaccination schedule. Journal of the American Medical Association. 1996;276:967-71.

**Miller M**, Valway S, Onoroto I. Tuberculosis risk after exposure on airplanes. Tubercle and Lung Disease. 1996;77:414-9.

Glass RI, Bresee JS, Parashar U, **Miller M**, Gentsch JR. Rotavirus vaccines at the threshold. Nature Medicine. 1997;3(12):1324-5.

The CVI Task Force on Strategic Planning. The CVI Strategic Plan Managing Opportunity and Change: A Vision of Vaccination for the 21<sup>st</sup> Century. Geneva: The Children's Vaccine Initiative, 1997.

**Miller MA**. An assessment of the value of *haemophilus influenzae* type B conjugate vaccine in Asia. Pediatric Infectious Disease Journal 1998; Oct (Supl3):S152-9.

**Miller MA**, Redd SC, Hadler S, Hinman A. A model to estimate the potential economic benefits of measles eradication for the United States. Vaccine, 1998; 20:1917-22.

**Miller MA**. Considerations for adding pneumonia and influenza vaccines to public health programs. Vaccine 1999; 17:S95-8.

**Miller MA**, Williams WW, Redd S. Measles in the United States adult population 1985-1995. American Journal of Preventive Medicine, 1999; 17:114--9.

**Miller MA**, Pisani E. The cost of unsafe injections. Bulletin of the World Health Organization, 1999; 77:808-11.

**Miller MA**, Wenger J, Rosenstien N, Perkins B. Evaluation of meningococcal meningitis control strategies for the meningitis belt in Africa. Pediatrics Infectious Disease Journal 1999; 18:1051-9.

**Miller MA**. Introducing a deterministic model to estimate global measles disease burden. Journal of International Infectious Diseases, 2000; 4:14-20.

**Miller MA**, McCann L. Policy analysis of the use of hepatitis b, *Haemophilus influenzae* type B-, *Streptococcus pneumoniae*- conjugate and rotavirus vaccines in national immunization schedules. Health Economics, 2000; 9:19-35.

Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, **Miller MA** Shinefield HR. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. *Journal of the American Medical Association*, 2000; 283:1460-8.

**Miller MA**, Flanders, D. A model to predict the probability of hepatitis b and *Haemophilus influenzae* type b vaccines into national immunization programs. *Vaccine*, 2000; 18:2223-2230.

**Miller MA**, Kane M. Routine hepatitis b immunization in India: Cost-effectiveness assessment. *Indian Journal of Pediatrics*, 2000; 67:299-300.

Freeman P, Miller M. Scientific Capacity building to improve population health: Knowledge as a global public good. WHO Commission on Macroeconomics and Health, Working Group 2: Global Public Goods. [http://www.cmhealth.org/docs/wg2\\_paper3.pdf](http://www.cmhealth.org/docs/wg2_paper3.pdf), 2001.

Binka F, Cash R, Chen L, Claeson M, Dare L, Doyal L, Evans T, Germain A, Horton R, Jones D, Kilima P, **Miller M**, Narasimhan V, Pablos-Mendez A, Ramsay S, Reddy KS, Sanders D, Suwanwela C, Thankappan KR, Wibulpolprasert S. An open letter to the Executive Board of WHO. *Lancet*. 2003 Jan 18;361(9353):194.

Parashar UD, Hummelman EG, Bresee JS, **Miller MA**, Glass RI. The global illness and deaths caused by rotavirus disease in children. *Emerging Infectious Disease*. 2003; 9:565-72.

Reichert TA, Sharma A, Simonsen L, Saito R, **Miller M**. Influenza and the winter increase in mortality in the United States, 1959-99. *American Journal of Epidemiology* 2004 160(5):492-502.

Forsyth KD, Campins-Marti M, Caro J, Cherry JD, Greenberg D, Guiso N, Heininger U, Schellekens J, Tan T, von Konig CH, Plotkin S for the Global Pertussis Initiative. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. *Clin Infect Dis*. 2004 Dec 15;39(12):1802-9.

Miller M, Shahab C. A review of the economics of meningococcal meningitis control. (Pharmacoeconomics-in press).

Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of Influenza Vaccination on Seasonal Mortality in the US Elderly Population. *Arch Intern Med*. 2005 Feb 14;165(3):265-72.

## BOOKS AND CHAPTERS

**Miller MA**, Hinman, A. Cost benefit and cost effectiveness analysis of vaccine policy. In Vaccines, Third Edition. Plotkin S and Orenstein W. eds. Philadelphia: W. B. Saunders Co. 1999. Pp. 1074-88.

**Miller MA**, Hinman, A. Economic Analyses of Vaccine Policies. In Vaccines, Fourth Edition. Plotkin S and Orenstein W. eds. Philadelphia: W. B. Saunders Co. 2004. Pp. 1463-90.

Keusch GT, Bart K, **Miller M**. Immunization Principles and Vaccine Use. In Harrison's Principles of Internal Medicine, Sixteenth Edition. Kasper D, Braunwald E, Fauci A, Hauser SL, Longo D and Jameson JL eds. New York: The McGraw-Hill Companies, Inc, 2004, 713-25.

Simonsen L, Reichert TA, Blackwelder WC, **Miller MA**. Benefits of influenza vaccination on Influenza-related mortality among elderly in the US: an unexpected finding. In Kawaoka, Y, (ed.) *International Congress Series 1263 Options for the control of influenza V* (2004):163-7.

Simonsen L, Reichert TA, **Miller MA**. The Virtues of antigenic sin: consequences of pandemic recycling on influenza-associated mortality. In Kawaoka, Y (ed.) International Congress Series 1263 Options for the control of influenza V (2004):791-4.

Simonsen L, Olson DR, Viboud C, Heiman E, **Miller MA**, Reichert TA. In Pandemic influenza and mortality: past evidence and projections for the future. In Institute of Medicine's Pandemic Influenza: Assessing Capabilities for Prevention and Response. Forum on Microbial Threats series, (2004). 1-26-46.

## **ABSTRACTS/LETTERS**

**Miller M**, Tachdjian R, Heath K, Strikas R, Williams W. Influenza vaccination amongst persons  $\geq 65$ : Who are we missing? Abstract accepted for Prevention 95 conference, New Orleans, March 30-April 3, 1995.

**Miller M**, Reichler M, Keegan R, Strebel P. Risk of poliomyelitis in United States Travelers to polio endemic areas. Abstract accepted for International Conference on Travel Medicine, Acapulco, April 23-27, 1995.

**Miller M**, Tachdjian R, Heath K, Strikas R, Williams W. Pneumococcal vaccination among persons  $> 65$ . American Journal of Respiratory and Critical Care Medicine. 151(4):A612, 1995.

**Miller M**, Eiseman M, Nelson M, Feldman G, Watson J. An outbreak of measles in adults: Are we maximizing prevention? Abstracts of the Thirty Fifth Annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.

**Miller M**, Tachdjian R, Strikas R, Williams W. Vaccination against pneumococcal infections and influenza: How are we doing? Abstracts of the 123rd Annual Meeting of the American Public Health Association, San Diego, October 29-November 2, 1995.

**Miller MA**, Legros JR, Strikas R, Williams W. Effect of medical conditions on influenza vaccination in the United States, 1993. Abstract of the 30th National Immunization Conference, Washington DC, April 1996.

Doshi SJ, **Miller M**, Schultz LJ, Strikas R, Williams W. Patterns of influenza and pneumococcal vaccination amongst women in the US. Abstract of the 30th National Immunization Conference, Washington DC, April 1996.

**Miller M**, Strikas R, Williams W. Vaccination against influenza amongst high risk persons in the US population. Abstracts of the Third Meeting of the Options to Control Influenza, Cairns, Australia, May 4-7, 1996.

Doshi SJ, Schultz LJ, **Miller MA**. Racial differences in influenza vaccination coverage among US women  $>65$  years, 1993. Abstracts of the Third Meeting of the Options to Control Influenza, Cairns, Australia, May 4-7, 1996.

**Miller M**, Williams W, Redd S. Measles in the adult US population. Abstracts of the Thirty Sixth Annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 17-20, 1996.

Whitney CG, Levine O, Robertson R, **Miller M**, Schwartz B. Cost-effectiveness of haemophilus influenzae type b conjugate immunization in developing countries. Abstracts of the Thirty Sixth Annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 17-20, 1996.

Doshi SJ, **Miller MA**, Schultz LJ, Lobel HO. Vaccination rates among US travelers to developing countries, 1986-1991. Abstracts of the 124th Annual Meeting of the American Public Health Association, New York City, November, 1996.

Legros J, **Miller MA**, Strikas R, Williams WW. Influenza and pneumococcal vaccination levels and receipt of other preventive health services. Abstracts of the 124th Annual Meeting of the American Public Health Association, New York City, November, 1996.

Sutter R, Strebel P, **Miller M**, Hadler S. Epidemiology of vaccine-associated paralytic poliomyelitis in the United States (letter). *Journal of the American Medical Association* (in press).

Silber JL, Strikas RA, Young G, **Miller M**, Paul S, Cetron MS, Breiman RF. Measuring the impact of a multifaceted pneumococcal vaccination program through an annual telephone survey. Abstract presented at the 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, September 13th -16th.

**Miller MA**, Wenger J, Rosenstien N, Perkins B. Evaluation of Meningococcal Meningitis Control Strategies for the Meningitis Belt in Africa. Abstracts of the Thirty Seventh Annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto September 28th -October 2nd, 1997.

**Miller MA**, Schwartz B. Assessment of Pneumococcal Conjugate Vaccine Incorporation into the Global Expanded Programme on Immunizations. Abstracts of the Thirty Seventh Annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto September 28th -October 2nd, 1997.

**Miller MA**, Redd SC, Hadler S, Hinman AR. Economic Benefits of Global Measles Eradication for the United States. Abstracts of the Thirty Seventh Annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto September 28th -October 2nd, 1997.

Singleton JA, **Miller M**, Strikas RA, Williams WW. Influenza vaccination of person with chronic cardiovascular disease, United States, 1989 through 1994. Abstracts of the 12<sup>th</sup> National Conference on Chronic Disease Prevention, Washington DC, December 3-5<sup>th</sup> 1997.

**Miller MA**. Hidden costs of unsafe injections. In World Health Organization/Global Programme for Vaccines and Immunization. Technical network for logistics in health Copenhagen consultation '98. Geneva, 1998.

**Miller M**, Widdus R, McCann L. New vaccine adoption into national immunizations programs. Nordic Vaccine Meeting, Helsinki, October 7-8, 1998.

**Miller M**, Strebel P, Olivé JM. More on measles (letter). *Public Health Reports*. 1999;114:4-5.

**Miller M**. Progress of vaccine adoption into national immunizations programs. *Clinical Microbiology and Infection*. 1999;5:44.

Lieu T, Ray GT, Black S, Shinefield H, Butler J, **Miller M**. Cost-effectiveness of Pneumococcal Vaccine. *JAMA* 2000 Jul 26;284(4):440-441.

**Miller M**. Adoption of Global Public Health Goods: The Case of Vaccines. Published in the proceedings of the World Medical Association Conference, Edinburgh, October, 2000.

Walker D, Fox-Rushby F, Sanderson C, Cutts F, **Miller M**. How useful are existing models for predicting the cost-effectiveness of introducing new vaccines? International Health Economics Association Conference, York, July 2001.

Parashar U, Hummelman E, Bresee J, **Miller MA**, Glass R. An Estimate of the Global Mortality from Rotavirus Disease in Children. Vaccines for Enteric Diseases VED 2001, Tampere, Finland, September 12-14, Finland.

Simonsen L, Reichert T, **Miller MA**. Effect of influenza vaccination in the United States: Prevention of mortality among the elderly. 1<sup>st</sup> European Influenza Conference, Malta October, 2000.

Reichert T, Simonsen L, **Miller MA**. The virtues of antigenic sin. 1<sup>st</sup> European Influenza Conference, Malta October, 2002).

Reichert T, Simonsen L, Sturke R, Depinay JM, **Miller MA**. Estimating the global burden of mortality due to influenza: building the tools. 1<sup>st</sup> European Influenza Conference, Malta October, 2002.

Simonsen L, Blackwelder, WC, Reichert TA, **Miller MA**. **Estimating deaths due to influenza and respiratory syncytial virus (letter)**. *JAMA*. 289 (19): 2499-2500.

Simonsen L, Reichert T, Blackwelder B, Miller M. A Marginal Impact of Influenza Vaccination Efforts on Influenza-related Mortality in US Elderly. Options for the control of influenza V, Okinawa, Japan, 2003, Oct 7-11.

Reichert T, Simonsen L, **Miller M**. The impact of influenza epidemics on seasonal mortality. Options for the control of influenza V, Okinawa, Japan, 2003, Oct 7-11.

Simonsen L, Reichert T, **Miller MA**. The Virtues of Antigenic Sin: Consequences of Pandemic Recycling on Influenza-associated Mortality. Options for the control of influenza V, Okinawa, Japan, 2003, Oct 7-11.

Viboud C, **Miller M**. *Space and time correlation of influenza epidemics in the United States: 1968-1998*. Options for the control of influenza V, Okinawa, Japan, 2003, Oct 7-11.

C Viboud, A Flahault, **M Miller**. Patterns of synchrony and coherence in influenza epidemics. Center for Discrete Mathematics and Theoretical Computer Science, Working Group on Spatio-Temporal and Network Modeling of Diseases, Rutgers University, USA, 2003, Apr 22-26.